Guerbet SA (EPA:GBT)

Market Cap	243.25M
Revenue (ttm)	851.12M
Net Income (ttm)	16.08M
Shares Out	12.60M
EPS (ttm)	1.28
PE Ratio	15.12
Forward PE	8.96
Dividend	0.50 (2.61%)
Ex-Dividend Date	Jul 1, 2024

Volume	2,037
Average Volume	10,779
Open	19.06
Previous Close	19.30
Day's Range	19.06 - 19.44
52-Week Range	17.42 - 39.35
Beta	0.79
RSI	31.32
Earnings Date	Sep 24, 2025

About Guerbet

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine; Elucirem, a macrocyclic gadolinium-based contrast agent; and Artirem, a gadoteric acid that acts a...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1926
• Employees: 2,905
• Stock Exchange: Euronext Paris
• Ticker Symbol: GBT

Financial Performance

In 2024, Guerbet's revenue was 851.12 million, an increase of 6.97% compared to the previous year's 795.65 million. Earnings were 16.08 million, a decrease of -32.61%.